Culture

Evidence supports Covid hearing loss link, say scientists

Hearing loss and other auditory problems are strongly associated with Covid-19 according to a systematic review of research evidence led by University of Manchester and NIHR Manchester Biomedical Research Centre (BRC) scientists.

Professor Kevin Munro and PhD researcher Ibrahim Almufarrij found 56 studies that identified an association between COVID-19 and auditory and vestibular problems.

They pooled data from 24 of the studies to estimate that the prevalence of hearing loss was 7.6%, tinnitus was 14.8% and vertigo was 7.2%.

They publish their findings in the International Journal of Audiology.

However, the team - who followed up their review carried out a year ago - described the quality of the studies as fair.

Their data primarily used self-reported questionnaires or medical records to obtain COVID- 7 19-related symptoms, rather than the more scientifically reliable hearing tests.

The study was funded by is NIHR Manchester Biomedical Research Centre (BRC)

Kevin Munro, Professor of Audiology at The University of Manchester and Manchester BRC Hearing Health Lead said: "There is an urgent need for a carefully conducted clinical and diagnostic study to understand the long-term effects of COVID-19 on the auditory system.

"It is also well-known that viruses such as measles, mumps and meningitis can cause hearing loss; little is understood about the auditory effects of the SARS-CoV-2 virus."

"Though this review provides further evidence for an association, the studies we looked at were of varying quality so more work needs to be done."

Professor Munro, is currently leading a year-long UK study to investigate the possible long-term impact of COVID-19 on hearing among people who have been previously treated in hospital for the virus.

His team hope to accurately estimate the number and severity of COVID-19 related hearing disorders in the UK, and discover what parts of the auditory system might be affected

They will also explore the association between these and other factors such as lifestyle, the presence of one or more additional conditions and critical care interventions.

A recent study led by Professor Munro, suggested that more than 13 per cent of patients who were discharged from a hospital reported a change in their hearing.

Ibrahim Almufarrij said: "Though the evidence is of varying quality, more and more studies are being carried out so the evidence base is growing. What we really need are studies that compare COVID-19 cases with controls, such as patients admitted to hospital with other health conditions.

"Though caution needs to be taken, we hope this study will add to the weight of scientific evidence that there is a strong association between Covid-19 and hearing problems."

Professor Munro added: "Over the last few months I have received numerous emails from people who reported a change in their hearing, or tinnitus after having COVID-19.

"While this is alarming, caution is required as it is unclear if changes to hearing are directly attributed to COVID-19 or to other factors, such as treatments to deliver urgent care."

Credit: 
Taylor & Francis Group

Eating processed meat could increase dementia?risk?

Scientists from the University of Leeds's Nutritional Epidemiology Group used data from 500,000 people, discovering that consuming a 25g serving of processed meat a day, the equivalent to one rasher of bacon, is associated with a 44% increased risk of developing the disease.

But their findings also show eating some unprocessed red meat, such as beef, pork or veal, could be protective, as people who consumed 50g a day were 19% less likely to develop dementia.

The researchers were exploring a potential link between consumption of meat and the development of dementia, a health condition that affects 5%-8% of over 60s worldwide.

Their results, titled Meat consumption and risk of incident dementia: cohort study of 493888 UK Biobank participants, are published today in the American Journal of Clinical Nutrition.

Lead researcher Huifeng Zhang, a PhD student from the University of Leeds' School of Food Science and Nutrition, said: "Worldwide, the prevalence of dementia is increasing and diet as a modifiable factor could play a role. Our research adds to the growing body of evidence linking processed meat consumption, to increased risk of a range of non-transmissible diseases."

The research was supervised by Professor Janet Cade and Professor Laura Hardie, both at Leeds.

The team studied data provided by UK Biobank, a database containing in-depth genetic and health information from half a million UK participants aged 40 to 69, to investigate associations between consuming different types of meat and risk of developing dementia.

The data included how often participants consumed different kinds of meat, with six options from never to once or more daily, collected in 2006-2010 by the UK Biobank. The study did not specifically assess the impact of a vegetarian or vegan diet on dementia risk, but it included data from people who said they did not eat red meat.

Among the participants, 2,896 cases of dementia emerged over an average of eight years of follow up. These people were generally older, more economically deprived, less educated, more likely to smoke, less physically active, more likely to have stroke history and family dementia history, and more likely to be carriers of a gene which is highly associated with dementia. More men than women were diagnosed with dementia in the study population.

Some people were three to six times more likely to develop dementia due to well established genetic factors, but the findings suggest the risks from eating processed meat were the same whether or not a person was genetically predisposed to developing the disease.

Those who consumed higher amounts of processed meat were more likely to be male, less educated, smokers, overweight or obese, had lower intakes of vegetables and fruits, and had higher intakes of energy, protein, and fat (including saturated fat).

Meat consumption has previously been associated with dementia risk, but this is believed to be the first large-scale study of participants over time to examine a link between specific meat types and amounts, and the risk of developing the disease.

There are around 50 million dementia cases globally, with around 10 million new cases diagnosed every year. Alzheimer's Disease makes up 50% to 70% of cases, and vascular dementia around 25%. Its development and progression are associated with both genetic and environmental factors, including diet and lifestyle.

Ms Zhang said: "Further confirmation is needed, but the direction of effect is linked to current healthy eating guidelines suggesting lower intakes of unprocessed red meat could be beneficial for health."

Professor Cade said: 'Anything we can do to explore potential risk factors for dementia may help us to reduce rates of this debilitating condition. This analysis is a first step towards understanding whether what we eat could influence that risk."

Credit: 
University of Leeds

Atomic techniques reveal the evolution of a bacterial protein

image: Using a synergistic approach, the collaborative KAUST team analyzed the reaction of different H-NS proteins (shown above) to temperature and salinity on an atomistic level.

Image: 
© 2021 KAUST; Vladlena Kharchenko

A combination of an array of atomic-level techniques has allowed researchers to show how changes in an environment-sensing protein enable bacteria to survive in different habitats, from the human gut to deep-sea hydrothermal vents.

"The study gives us unprecedented atomic-level insight into how bacteria adapt to changing conditions," says Stefan Arold, professor of bioscience at KAUST. "To obtain these insights, we pushed the limits of three different methods of investigation and combined their results into a unified picture."

The histone-like nucleoid-structuring (H-NS) protein allows bacteria to sense changes in their environment, such as changes in temperature and salinity. Previously, the team had shown how the intestinal pathogen Salmonella typhimurium uses H-NS to control its gene expression profile, enabling it to live optimally inside its warm-blooded host or outside in the soil.

The H-NS protein is also found in bacteria that do not experience massive temperature fluctuations, such as plant pathogens, insect symbionts and free-living microbes that inhabit deep-sea hydrothermal vents. Still puzzling, however, is how different bacteria have adapted the same sensing mechanism to suit a variety of lifestyles.

No single analysis technique has been able to unravel the inner workings of this mechanism and so, to gain a more integrated view, Arold assembled a diverse team from KAUST and international collaborators. Arold and Lukasz Jaremko, a molecular biochemist at KAUST, collaborated with Jianing Li from the University of Vermont to combine several methods: protonless nuclear magnetic resonance spectroscopy, all-atom molecular dynamics simulations and biophysics techniques. This synergistic approach allowed the researchers to analyze the reaction of different H-NS proteins to temperature and salinity on an atomistic level.

All H-NS proteins displayed the same ancestral sensing mechanism, whereby temperature and salinity promoted melting of one of the two dimerization domains of H-NS, releasing its grip on DNA.

However, site-specific amino acid substitutions, mostly in residues involved in salt bridges, produced a range of static and dynamic features. These effects dampen or amplify the protein's response to suit the bacteria's lifestyle.

"Although the sequences of these proteins are largely conserved, small targeted changes lead to big differences in how they behave," says KAUST research scientist Umar Farook Shahul Hameed.

Thus, the H-NS protein of the apple pathogen Erwinia amylovora lost its sensitivity to heat, which is consistent with the pathogen's lifestyle in stable temperate climates. And only a few amino-acid changes made H-NS from Buchnera aphidicola almost environment insensitive, in line with its role as an obligate endosymbiont of aphids.

"If you tickle the right positions, the behavior changes very easily," says Arold. "Approaches interfering with this sensing mechanism might find applications in areas ranging from climate change mitigation to tackling antibiotic resistance".

Credit: 
King Abdullah University of Science & Technology (KAUST)

Shell middens rewrite history of submerged coastal landscapes in North America & Europe

video: An international team of archaeologists from Moesgaard Museum (Denmark), the University Of Georgia (USA), the University of York (UK) Flinders University and James Cook University partnered to excavate two sites containing shell middens in the Gulf of Mexico and Eastern Jutland in Denmark.

Image: 
Deep History Of Sea Country Project, Flinders University.

The excavation of shell middens off two sites in the Gulf of Mexico and Northern Europe dating back to when the seabed was dry land thousands of years ago, reveal how they can offer new ground-breaking insights into the hidden history of submerged landscapes.

An international team of archaeologists from Moesgaard Museum (Denmark), the University Of Georgia (USA), the University of York (UK) Flinders University and James Cook University partnered to excavate two sites containing shell middens in the Gulf of Mexico and Eastern Jutland in Denmark in 2018, showing that middens can be clearly differentiated from natural shells on the seabed to reveal a coastline’s inhabitation past.

The research, published in two companion papers in Quaternary Science Reviews, shows they are culturally significant underwater sites which challenge the current understanding of coastal life in the Gulf of Mexico and Northern Europe, by pushing back the inhabitation timeframe by hundreds of years.

The shell middens also represent deep connections with the underwater environments and seascapes to many First Nations people, and the new evidence will support policy changes towards the adequate management and cultural heritage of their ancestral land.

“Shell middens are a classic, world-wide marker for the intensive use of marine resources, but archaeologist have always assumed that these sites would have been destroyed by sea-level rise”, says Professor Geoff Bailey of the University of York and Visiting Professor at Flinders University.

In Denmark, the discovery of these shell middens, which are rare in the south, hints that this type of site was more common than previously thought, shifting understandings of how intensive coastal use was 5000-7300 years ago.

“Importantly, both studies show that as more of these sites are found, our histories of past coastal use may have to be rewritten. The underwater archaeological aspect to shell midden studies is extremely important moving forward,” says Dr Peter Moe Astrup, Lead Author and Curator of the Maritime Archaeology division at the Moesgaard Museum in Denmark.

“The team of archaeologists used cutting-edge techniques, including microscopy, geological and geophysical techniques, 3D reconstructions, and biological and ecological studies to tease out evidence that offers new insights into midden sites, particularly on how to locate other sites in watery depths around the globe.”

“For a large portion of humanity’s existence, sea levels have been significantly lower, up to 130 metres than what they are today, exposing millions of square kilometres of land. And the archaeological record clearly demonstrates that people in the past lived on these coastal plains before they were drowned by past sea-level rise” says Associate Professor Jonathan Benjamin who is the Director of the Deep History of Sea Country Project and Maritime Archaeology Program Coordinator at Flinders University's College of Humanities, Arts and Social Sciences.

"Within archaeological shell middens, we can find old food remains, discarded tools and ornaments, old living surfaces, and in some cultures, human burials,” says Dr Katherine Woo at the Australian Research Council Centre of Excellence for Australian Biodiversity and Heritage, James Cook University in Australia.

“These in turn provide us with fundamental information about past food choices, tool technology, and trade practices. More importantly, these different types of information allow us to understand how people adapted their cultures over time, and how they interacted with their surrounding environments including during times of sea level rise and climate change.”

The excavation of these sites emphasises the need for stronger recognition and rights to protect and manage the cultural heritage of underwater ancestral lands around the globe, which hold significant insights into human history and deep connections to marine environments.

“The discovery of these underwater sites, and the promise of more to be found, means that industry, developers, archaeologists, and government bodies must reassess how we classify and handle Indigenous heritage on the continental shelf,” says Dr Jessica Cook Hale from the University of Georgia. “This is especially critical because offshore development is accelerating; here in North America the big push for offshore windfarms is underway, but Indigenous voices must remain foremost. These new findings support ongoing work to ensure that Indigenous and First Nations have a critical seat at the table, so to speak, in managing the offshore cultural heritage of their ancestral lands by documenting these relationships into the deep past.”

“They are real, they are important, and we must all engage with them in a rigorous and serious fashion.

Credit: 
Flinders University

Spanish-speaking children experience higher rate of obesity than English-speaking children

WASHINGTON--Nearly one in five U.S. children and teenagers has obesity, and statistics show a higher prevalence of obesity in certain ethnicities, such as Hispanics and Blacks. Now results of a study being presented at ENDO 2021, the Endocrine Society's annual meeting, suggest that Spanish as a family's primary language is a predictor of childhood obesity, regardless of ethnicity.

The prevalence of obesity among children and teens from Spanish-speaking households in the nation was 24.4 percent, approximately 50 percent higher than those from English-speaking households, according to results of a new analysis of the U.S. National Health and Nutrition Examination Survey. This survey examines a nationally representative sample of the U.S. population each year, and the study researchers used statistics from the 1999 to 2018 surveys regarding 2- to 19-year-olds. The survey found overall obesity among this age group climbed to 19.2 percent in 2018, up from 14.7 percent in 1999.

"Childhood obesity is associated with multiple diseases in adulthood," said the Hang-Long ("Ron") Li, a medical student at the University of Hong Kong (HKU) LKS Faculty of Medicine in Hong Kong, China, who carried out the analysis under the supervision of Prof. Bernard M.Y. Cheung, Ph.D., the Sun Chieh Yeh Heart Foundation Professor in Cardiovascular Therapeutics at HKU. "Public health measures specifically catering to children from Spanish-speaking families should be put in place to raise awareness of childhood obesity and implement health interventions."

Li said they are the first group to identify an association between childhood obesity and language. He speculated that language barriers could prevent Spanish-speaking families from understanding health education materials or accessing Spanish-language health promotion resources. Additionally, he noted that food labels, which play an important role in obesity prevention efforts, may be in English only. Alternatively, these families may be aware of available health materials but are not taking action to make essential lifestyle changes.

Existing programs to combat childhood obesity should be promoted to Spanish-speaking households and should be sensitive to different cultural traditions, Li said.

"Health talks and activities could also be carried out in Spanish to improve the dissemination of important public health knowledge, such as healthy eating and physical activity," he said.

The researchers also found that obesity is more prevalent in children from households with a low socioeconomic status. The obesity rate was 23.8 percent in children from low-income households versus 11 percent for children in high-income households, they reported. Likewise, the prevalence of obesity was 26.2 percent in children from households with a low educational level compared with 9.4 percent from highly educated families.

Measures to halt this trend could include promotion of healthy school meals and improved accessibility and affordability of nutritious fresh foods in poor communities, Li said.

The researchers looked at U.S. trends in childhood obesity over the last two decades and found a large increase in overall obesity among 2- to 19-year-olds. Severe obesity at those ages increased from 3.9 to 6.1 percent in the same period, a more than 55 percent upsurge, Li reported.

In children, severe obesity is weight at or above the 120th percentile for age and sex, and the definition of obesity is weight at or greater than the 95th percentile.

"Improved public health interventions are urgently needed to halt the rising trend of childhood obesity," Li said.

Credit: 
The Endocrine Society

Children with adrenal insufficiency are 10 times more likely to die from COVID-19

WASHINGTON--Children with adrenal insufficiency--a condition in which the adrenal gland does not function properly--are at more than 10 times higher risk for COVID-19 complications and death compared with children with normal adrenal glands, according to a study presented virtually at ENDO 2021, the Endocrine Society's annual meeting.

Adrenal insufficiency is a disorder that occurs when the adrenal glands, located just above the kidneys, don't make enough of the hormone cortisol. The primary form of adrenal insufficiency is also called Addison's disease. Known as the "stress hormone," cortisol helps break down fats, proteins and carbohydrates. It also controls blood pressure and affects the immune system. Children with adrenal insufficiency are treated with daily cortisol replacement therapy. They need increased doses when they are sick.

"Adrenal insufficiency may put a person at higher risk of infections due to a lack of normal stress response by the body," said lead researcher Manish Rasingani, M.D., of the University of Arkansas for Medical Sciences and Arkansas Children's in Little Rock, Ark. "Until now, there has been limited data on children with adrenal insufficiency and COVID-19."

In the new study, the researchers analyzed data from an international database on children up to age 18 who had COVID-19. The study included 846 children with adrenal insufficiency and more than 250,000 without adrenal disease. The mortality rate was much higher among children who had adrenal insufficiency, compared to children who did not have the condition.

"This study shows it is important to take extra precautions to prevent and treat COVID-19 infection in children with adrenal insufficiency," Raisingani said.

Credit: 
The Endocrine Society

White button mushrooms could slow progression of prostate cancer

WASHINGTON--The chemicals present in white button mushrooms may slow the progression of prostate cancer, according to a mouse study presented virtually at ENDO 2021, the Endocrine Society's annual meeting.

"Androgens, a type of male sex hormone, promote the growth of prostate cancer cells by binding to and activating the androgen receptor, a protein that is expressed in prostate cells," said lead researcher Xiaoqiang Wang, M.D., Ph.D., M.B. (A.S.C.P.), of the Beckman Research Institute of City of Hope, a comprehensive cancer center in Duarte, Calif. "White button mushrooms appear to suppress the activity of the androgen receptor."

City of Hope's Shiuan Chen, Ph.D., the principal investigator of this project, previously conducted a phase one clinical trial of white button mushroom powder in patients with recurrent prostate cancer, which indicated that the mushrooms reduced levels of prostate-specific antigen (PSA) in the blood, with minimal side effects. Heightened blood levels of PSA in men may indicate the existence of prostate tumors.

The new study aimed to understand the mechanism behind this finding. The researchers studied the mushroom extract's effect on prostate cancer cells that were sensitive to androgen. They also studied the extract's effect on mice implanted with human prostate tumors, which creates an animal model whose results would be more reliable as the research is translated to human clinical trials.

The researchers found that in prostate cancer cells, white button mushroom extract suppressed androgen receptor activity. They also found that in mice treated with white button mushroom extract for six days, prostate tumor growth was significantly suppressed, and levels of PSA decreased.

"We found that white button mushrooms contain chemicals that can block the activity of the androgen receptor in mouse models, indicating this fungus can reduce PSA levels," Wang said. "While more research is needed, it's possible that white button mushrooms could one day contribute to the prevention and treatment of prostate cancer."

Credit: 
The Endocrine Society

Supplements may protect those with low vitamin D levels from severe COVID-19

WASHINGTON--Patients with low vitamin D levels who are hospitalized for COVID-19 may have a lower risk of dying or requiring mechanical ventilation if they receive vitamin D supplementation of at least 1,000 units weekly, according to a study presented virtually at ENDO 2021, the Endocrine Society's annual meeting.

"Given how common vitamin D deficiency is in the world and the United States, we believe that this research is highly relevant right now," said co-author Sweta Chekuri, M.D., of Montefiore Health System and Albert Einstein College of Medicine in the Bronx, New York.

Research has shown that vitamin D supplementation can prevent inflammation in other respiratory diseases, but there have been limited studies examining the role of vitamin D supplementation in COVID-19. The purpose of the study was to determine whether being supplemented with vitamin D before being admitted to the hospital with COVID-19 resulted in less severe COVID-19 disease in patients with a low vitamin D level.

The researchers studied 124 adult patients with low vitamin D that was measured up to 90 days before their admission for COVID-19. They compared the patients who were supplemented with at least 1,000 units of vitamin D weekly to those who had not received vitamin D supplements in terms of whether they were mechanically ventilated or died during admission.

They found that patients who were supplemented were less likely to be mechanically ventilated or to die following admission, though the finding wasn't statistically significant (37.5 percent of patients who were not supplemented vs. 33.3 percent of those who were) They also found that more than half of those who should have been supplemented were not.

"Though we weren't able to show a definitive link to severe COVID-19, it is clear that patients with low vitamin D should receive supplementation not only for bone health, but also for stronger protection against severe COVID-19," said co-author Corinne Levitus, D.O., of Montefiore Health System and Albert Einstein College of Medicine. "We hope this research will encourage clinicians to discuss adding this supplement with their patients who have low vitamin D, as this may reduce the odds of people developing severe COVID-19."

A study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism last fall found over 80 percent of 200 COVID-19 patients in a hospital in Spain had vitamin D deficiency.

Credit: 
The Endocrine Society

Hospitalized COVID-19 patients fare worse when they have high blood sugar

WASHINGTON--Patients hospitalized with COVID-19 have worse outcomes if they have high blood sugar, or hyperglycemia, regardless of whether they have diabetes, a new study finds. The researchers will present their results, of the first known study of the impact of hyperglycemia on a largely Black patient population with the novel coronavirus, at ENDO 2021, the Endocrine Society's annual meeting.

The investigators found that patients with COVID-19 who had hyperglycemia on admission to the hospital were more likely than those with normal glucose (sugar) to require a breathing machine or admission to the intensive care unit (ICU). These patients also were reportedly likelier to have kidney injury and to die in the hospital.

"COVID-19 patients presenting to the hospital with hyperglycemia require closer observation, as they are likely to require more aggressive therapies," said the study's lead investigator, Samara Skwiersky, M.D., M.P.H., an internal medicine resident physician at the State University of New York (SUNY) Downstate Medical Center in Brooklyn, N.Y.

Although a few prior studies have identified hyperglycemia or diabetes as an independent risk factor for worse COVID-19 outcomes, Skwiersky said they did not take place in a predominantly Black population. The virus has disproportionately affected Black people, including higher rates of hospitalization and death than in white people, she noted.

Their study included 708 adults with COVID-19 admitted to SUNY Downstate Medical Center, 89 percent of whom were Black. About half were men, and 54 percent of patients had a history of either type 1 or type 2 diabetes on admission.

The researchers studied patient outcomes by the presence or absence of diabetes and by their blood glucose values on admission. Because guidelines recommend that hospitalized patients with diabetes maintain blood glucose levels between 140 and 180 milligrams per deciliter (mg/dL), the investigators divided patients into groups by glucose levels less than 140 and less than 180 mg/dL.

Patients with diabetes whose blood glucose values on admission exceeded 140 mg/dL had a 2.4-fold increased odds of ICU admission and intubation--needing a breathing machine--versus those whose glucose levels were lower, the researchers reported. Furthermore, patients with diabetes whose admission glucose levels were higher than 180 mg/dL had an approximately twofold increased odds of in-hospital death, their data showed.

However, Skwiersky said the odds of death also were increased twofold for patients who did not have diabetes and whose glucose values exceeded 140 mg/dL. Additionally, these patients had a 3.5-fold raised odds of ICU admission and a 2.3-fold higher odds of intubation and of experiencing acute kidney injury.

According to Skwiersky, patients without diabetes whose blood glucose levels topped 180 mg/dL had a fourfold greater death risk, a nearly threefold increased odds of ICU admission, and a 2.7-fold higher odds of intubation.

"The results from our study," she said, "reiterate the importance of regularly monitoring blood glucose in patients hospitalized with COVID-19, even without a prior diagnosis of diabetes."

It is unclear whether hyperglycemia is the result of or a cause of more severe COVID-19 illness, Skwiersky stated. Still, she said their results suggest the need for intensive glucose control in hospitalized COVID-19 patients with high blood sugar. This is consistent with the current Endocrine Society guidelines, which recommend that all patients with blood glucose above 140 mg/dL be monitored with point-of-care glucose testing and treated with appropriate therapies.

"More frequent glucose monitoring and treatment with insulin therapy to a target glucose value less than 140 mg/dL could improve outcomes in these patients," Skwiersky said.

Credit: 
The Endocrine Society

Tubeless automated insulin delivery system improves blood glucose outcomes

WASHINGTON--People with type 1 diabetes can improve their blood sugar control while reducing time with low blood sugar, or hypoglycemia, using Insulet Corporation's Omnipod 5 Automated Insulin Delivery System compared to their standard insulin therapy. Results from an industry-sponsored study of the latest Omnipod, the first tubeless, wearable insulin pump, will be presented at ENDO 2021, the Endocrine Society's annual meeting.

The Omnipod 5 System underwent three months of at-home testing in 128 adults and adolescents ages 14 to 70 years and 112 children ages 6 to less than 14 years. All study participants have type 1 diabetes and were first followed for two weeks using their standard therapy, either multiple daily insulin injections or an insulin pump. Using Omnipod 5, participants experienced significant average improvements in both hemoglobin A1c, a measure of blood glucose (sugar) control over the past several months, and the percentage of time the participants stayed within the recommended target glucose range (70 to 180 milligrams per deciliter), the researchers reported.

"These study results represent an advancement in diabetes therapies with a fully wearable device that enables continuous automated insulin modulation. This will expand the available treatment options for people with type 1 diabetes," said the study's senior investigator, Trang Ly, MBBS, FRACP, PhD, Senior Vice President and Medical Director of Insulet Corporation.

Insulet funded this study and manufactures Omnipod 5, which is under review by the U.S. Food and Drug Administration. It is an update to the Omnipod DASH and the original Omnipod System, which are sold in the U.S., Canada, Europe and the Middle East.

The Omnipod 5 System, according to Ly, is the first tubeless automated insulin delivery system integrated with the Dexcom G6 continuous glucose monitoring (CGM) system. She said this commonly used glucose monitor automatically measures glucose levels every five minutes and communicates directly with Omnipod 5. The Pod is now designed with an embedded algorithm that adjusts the pump's insulin delivery automatically to a customizable glucose target, based on the CGM value and trend.

Users of Omnipod 5 inject insulin into a single-use Pod, which adheres to their skin for 72 hours of continuous infusion of insulin. At mealtimes, the user administers a bolus dose of insulin which is controlled by the Omnipod 5 app on the user's personal smartphone or a separate wireless controller. Ly said the new system will have the ability to control the Pod from a compatible smartphone, making the wireless controller optional.

Ly reported that the adult/adolescent group's A1c averaged 0.4 percent lower with Omnipod 5 than when they used their standard insulin therapy, an improvement from 7.2 percent to 6.8 percent.

With Omnipod 5, their average time in the glucose range recommended by the American Diabetes Association (70 to 180 milligrams per deciliter) was 2.2 hours a day longer, or 9.3 percent better, Ly stated. Overall, this group was in target range nearly 74 percent of the time when they used Omnipod 5, while the general population with type 1 diabetes is often in target glucose range 60 percent or less of the time.

"Even though many of the study participants had their diabetes well controlled before the study, they still experienced improved time in the target glucose range, regardless of their baseline control. This shows the potential of the technology in the broader population with diabetes," Ly said.

One of their most important findings in the adult/adolescent group, according to Ly, was a reduction of time in hypoglycemia, measured on the sensor as glucose levels below 70 milligrams per deciliter, down to a median of 1.1 percent. Hypoglycemia is a dangerous drop in blood glucose levels. Only two episodes of severe hypoglycemia occurred, reportedly after user-initiated bolus doses.

Most study participants chose to continue using the Omnipod 5 during an extension of the original three-month study, which Ly said suggests a preference over their previous therapy.

Children participating in the study also had improved blood sugar control after using Omnipod 5. The average A1c dropped by 0.7 percent, to 7 percent, and the time in range improved by nearly four hours per day. One event of diabetic ketoacidosis (excessive ketones in the blood due to insufficient insulin) occurred, which Ly attributed to infusion site failure. She said one severe hypoglycemia event occurred that was not attributable to device malfunction.

"Omnipod 5 protects you from both high and low glucose values," Ly said. "It also is simple, intuitive, and easy to use."

Sue Brown, M.D., of the University of Virginia in Charlottesville, Va., will present the data for adults and adolescents during an oral presentation at the meeting. Bruce Buckingham, M.D., of Stanford University, will present the pediatric data in a poster presentation.

Credit: 
The Endocrine Society

Researchers use AI to estimate focal mechanism parameters of earthquake

The research team led by Prof. ZHANG Jie from the University of Science and Technology of China (USTC) of the Chinese Academy of Sciences made progress on real-time determination of earthquake focal mechanism through deep learning. The work was published in Nature Communications.

Since there are connections between characteristics of the rupture surface of the source fault and seismic wave radiated by the source, it's vital to monitor the earthquake by immediate determination of the source focal mechanism which inferred from multiple ground seismic records.

However, it's hard to calculate the mechanism from the simple records. The parameters about focal mechanism are either merely reported or reported after a few minutes even longer.

In this study, Prof. ZHANG's team applied a novel convolutional neural network to solve this problem effectively, paving the way for the acceleration of the investigation of details about earthquake.

The neural network, named as Focal Mechanism Network (FMNet), was first trained to estimate the source focal mechanism rapidly using full waveforms. Then, the neural network model was trained by comprehensive dataset, which modified the report system. After the earthquake, the real-dataset are introduced into the training system, the estimated parameters about the earthquake source can be calculated within one second with a minimum requirement of computing resources and memory storage.

A large number of practical data tests have proved the effectiveness of the method.

The results of this study are now being translated into practical functions and will soon be put into trial operation on the intelligent ground motion artificial intelligence earthquake monitoring system jointly developed by USTC and China Earthquake Administration.

Credit: 
University of Science and Technology of China

In pandemic, potentially avoidable hospitalizations for non-COVID conditions fell more among whites

During the first six months of the pandemic, as people attempted to stay away from hospitals caring for those sick with COVID-19, potentially avoidable hospitalizations for non-COVID-19-related conditions fell far more among white patients than Black patients, according to a new study that looked at admissions to UCLA Health hospitals.

The findings indicate that the COVID-19 crisis has exacerbated existing racial health care disparities and suggest that during the pandemic, African Americans may have had worse access than whites to outpatient care that could have helped prevent deterioration of their non-COVID-19 health conditions, said Dr. Richard Leuchter, a resident physician at UCLA Health and lead author of the study, to be published in the American Journal of Preventive Medicine.

These hospitalizations -- for conditions ranging from diabetes and asthma to hypertension -- disproportionately expose African Americans to the financial burdens of missing work and hospital costs, separate them from their families and increase their risk of hospital-acquired infections, the researchers say.

"At a time when large-scale community activism has brought attention to systemic racial injustices, it's important to bring these inequities to light so that action can be taken," Leuchter said. "While these findings are limited to UCLA Health, these problems represent a systemwide challenge for health care that cannot be addressed through the actions of a single institution.

"It is within our power as a society to reallocate resources to combat these serious health inequities," he added. "We need widespread community action."

Consistent with national trends that emerged as patients avoided hospitals treating individuals with COVID-19, potentially avoidable hospitalizations dropped across UCLA Health hospitals during the pandemic. Research into this phenomenon is ongoing, but the current study suggests that the potential benefits associated with avoiding the hospital were not shared equally among white and Black patients.

The researchers examined records for patients admitted to UCLA Health hospitals between March 1 and Aug. 31, 2020, and compared them with hospitalizations during the same pre-pandemic months of 2019. Patients were admitted for chronic obstructive pulmonary disease, asthma, hypertension, congestive heart failure, community-acquired pneumonia, uncontrolled diabetes and diabetes complications, and urinary tract infections. People with these conditions can often avoid hospitalization with appropriate outpatient treatment.

The researchers found that out of 4,838 hospitalizations during the 2020 time period, 347 (7.2%) were potentially avoidable, compared with 557 out of 6,248 (8.9%) hospitalizations during the same six-month period in 2019. While such hospitalizations dropped by 50% for non-Hispanic whites from 2019 to 2020, they dropped a statistically insignificant 8% for African Americans.

In addition to the wide disparity between white and Black patients, the researchers found that avoidable hospitalizations fell 32.3% for Latinos and 16.1% for Asians over the same periods, although they note that the "relative differences in magnitudes of reduction were only statistically significant between African American and non-Hispanic white patients."

The study has some limitations, the researchers say. For instance, it did not take into account factors like comorbidities or socioeconomic status that could contribute to health disparities. In addition, the sample was confined to a single health system, there was an assumption that the population pools from 2019 and 2020 were similar, and some patients may have received false negative results on COVID-19 tests, leading doctors to admit them for pneumonia, which the study classifies as a potentially avoidable hospitalization.

But the findings could still guide health officials in identifying racial and ethnic groups with these largely treatable conditions and ensuring that they have access to outpatient care that could prevent unnecessary hospitalizations, Leuchter said.

"A campaign to reduce avoidable hospital admissions could have an enormous positive impact on people of color by minimizing the harms to which they are exposed through such hospitalizations," he said.

Credit: 
University of California - Los Angeles Health Sciences

Starving tumors by blocking glutamine uptake

image: Ze'ev Ronai, Ph.D., director of Sanford Burnham Prebys' NCI-Designated Cancer Center.

Image: 
Sanford Burnham Prebys Medical Discovery Institute

LA JOLLA, CALIF. - March 19, 2021 - Scientists at Sanford Burnham Prebys Medical Discovery Institute have identified a drug candidate that blocks the uptake of glutamine, a key food source for many tumors, and slows the growth of melanoma. The drug is a small molecule that targets a glutamine transporter, SLC1A5, which pumps the nutrient into cancer cells--offering a promising new approach for treating melanoma and other cancers. The study was published in the journal Molecular Cancer Therapeutics.

"While great strides have been made recently in the treatment of melanoma, many patients' tumors become resistant to therapy, and this has become a major obstacle in the successful treatment of the disease," says Ze'ev Ronai, Ph.D., director of the National Cancer Institute (NCI)-designated Cancer Center at Sanford Burnham Prebys and senior author of the study. "This study describes a promising compound that selectively targets the uptake of glutamine, an amino acid nutrient that tumors rely on for survival. We are hopeful this drug will fill an unmet medical need for people living with this deadly cancer."

More than 7,000 people die from melanoma each year in the U.S., according to the American Cancer Society, and cases continue to increase annually. In the past decade, immunotherapy and personalized treatments have extended survival times for many patients. However, because of the high incidence of cancer recurrence, scientists are increasingly focused on therapeutic strategies to prevent relapse and increase overall survival.

"This is a very important study because many targeted drugs for melanoma treatment have been significantly hindered by the rapid development of treatment resistance, sometimes as quickly as within several months. While immunotherapy approaches are promising, they are only effective in a subset of patients, and treatment resistance can also develop in this setting as well," says M. Celeste Simon, Ph.D., Arthur H. Rubenstein, MBBCh Professor in the department of Cell and Developmental Biology and scientific director of the Abramson Family Cancer Research Institute at the Perelman School of Medicine at the University of Pennsylvania. "The drug candidate identified in Dr. Ronai's study offers an exciting new therapeutic approach for treating tumors addicted to glutamine, which includes a long list of human cancers, and will hopefully lengthen the amount of time that people with melanoma respond to available treatments."

Blocking the tumor's food supply

Researchers know that rapidly growing tumors are able to reprogram their metabolism to generate extra energy to survive and grow. Tumors often achieve this by pumping increasing levels of the amino acid glutamine into their cells, primarily through a pump called SLC1A5. As a result, cancer researchers are working to find drugs that block SLC1A5 and reduce glutamine levels.

In the study, Ronai and his team set out to identify drug(s) that can inhibit glutamine uptake. Working in collaboration with researchers at the Institute's Conrad Prebys Center for Chemical Genomics, the scientists screened 7,000 diverse compounds for their ability to interfere with SLC1A5. This work identified about 20 hits, or promising options, and one was selected based on its superior ability to prevent SLC1A5 from reaching the cell membrane. This drug candidate, IMD-0354, inhibited tumor growth in both cell culture and in mice with melanoma.

"Our study shows that targeting SLC1A5, which stops glutamine from ever entering the cell in the first place, is an effective way to slow cancer cell growth," says Yongmei Feng, Ph.D., staff scientist in the Ronai lab at Sanford Burnham Prebys and first author of the study. "Because many tumor types are dependent upon glutamine for survival, this drug may be able to treat many different types of cancers."

As a next step, Ronai and his team will further refine IMD-0354, with a focus on improving biophysical properties that will help accelerate preclinical evaluation of the drug candidate.

Credit: 
Sanford Burnham Prebys

Maintaining body weight won't save colorectal cancer survivors

image: Justin C. Brown, Ph.D., assistant professor and director, Cancer Metabolism Program at Pennington Biomedical Research Center

Image: 
Pennington Biomedical Research Center

Colorectal cancer survivors who maintained a stable body weight but lost muscle and developed fatty deposits in their muscles faced a 40 percent higher risk of premature death than patients who avoided both health issues.

"The conventional wisdom has been that colorectal cancer patients should avoid losing or gaining weight during treatment," said Dr. Justin C. Brown, Assistant Professor and Director of the Cancer Metabolism Program at Pennington Biomedical Research Center. "But maintaining your weight does not mean your body composition remains the same. Muscle can change quite dramatically, and those changes are associated with a much higher risk of death."

The researchers say assessing body composition by computed tomography images may be a vital method of identifying patients at increased risk of death.

This study highlights how body composition can have a powerful impact on long-term health. We at Pennington Biomedical are committed to conducting innovative research to enable cancer survivors around the world to achieve their best possible health," said Dr. John Kirwan, Executive Director.

The study, published in The American Journal of Clinical Nutrition, looked at 1,921 patients with stage I-III colorectal cancer. Skeletal muscle and body weight were measured at diagnosis and an average of 15 months later. Stable body weight was defined as being within plus or minus 5 percent of weight at diagnosis.

Researchers found that stable body weight masks clinically meaningful skeletal muscle depletion. Women were particularly vulnerable to losing muscle. One in five women with stable body weight lost muscle, while less than one in 10 men did.

"More research is needed to determine whether physical activity offers the best solution to prevent muscle loss or fatty deposits in muscle," Dr. Brown said. "But the findings provide colorectal cancer patients with more incentive to engage in physical activity programs that maintain and build muscle."

Credit: 
Pennington Biomedical Research Center

Tiny machine poised to unlock brain's mysteries

image: Three dimensional multifunctional neural interfaces for cortical spheroids and engineered assembloids

Image: 
Northwestern University

A team of scientists, led by researchers at Northwestern University, Shirley Ryan AbilityLab and the University of Illinois at Chicago (UIC), has developed novel technology promising to increase understanding of how brains develop, and offer answers on repairing brains in the wake of neurotrauma and neurodegenerative diseases.

Their research is the first to combine the most sophisticated 3-D bioelectronic systems with highly advanced 3-D human neural cultures. The goal is to enable precise studies of how human brain circuits develop and repair themselves in vitro. The study is the cover story for the March 19 issue of Science Advances.

The cortical spheroids used in the study, akin to "mini-brains," were derived from human-induced pluripotent stem cells. Leveraging a 3-D neural interface system that the team developed, scientists were able to create a "mini laboratory in a dish" specifically tailored to study the mini-brains and collect different types of data simultaneously. Scientists incorporated electrodes to record electrical activity. They added tiny heating elements to either keep the brain cultures warm or, in some cases, intentionally overheated the cultures to stress them. They also incorporated tiny probes -- such as oxygen sensors and small LED lights -- to perform optogenetic experiments. For instance, they introduced genes into the cells that allowed them to control the neural activity using different-colored light pulses.

This platform then enabled scientists to perform complex studies of human tissue without directly involving humans or performing invasive testing. In theory, any person could donate a limited number of their cells (e.g., blood sample, skin biopsy). Scientists can then reprogram these cells to produce a tiny brain spheroid that shares the person's genetic identity. The authors believe that, by combining this technology with a personalized medicine approach using human stem cell-derived brain cultures, they will be able to glean insights faster and generate better, novel interventions.

"The advances spurred by this research will offer a new frontier in the way we study and understand the brain," said Shirley Ryan AbilityLab's Dr. Colin Franz, co-lead author on the paper who led the testing of the cortical spheroids. "Now that the 3-D platform has been developed and validated, we will be able to perform more targeted studies on our patients recovering from neurological injury or battling a neurodegenerative disease."

Yoonseok Park, postdoctoral fellow at Northwestern University and co-lead author, added, "This is just the beginning of an entirely new class of miniaturized, 3-D bioelectronic systems that we can construct to expand the capacity of the regenerative medicine field. For example, our next generation of device will support the formation of even more complex neural circuits from brain to muscle, and increasingly dynamic tissues like a beating heart."

Current electrode arrays for tissue cultures are 2-D, flat and unable to match the complex structural designs found throughout nature, such as those found in the human brain. Moreover, even when a system is 3-D, it is extremely challenging to incorporate more than one type of material into a small 3-D structure. With this advance, however, an entire class of 3-D bioelectronics devices has been tailored for the field of regenerative medicine.

"Now, with our small, soft 3-D electronics, the capacity to build devices that mimic the complex biological shapes found in the human body is finally possible, providing a much more holistic understanding of a culture," said Northwestern's John Rogers, who led the technology development using technology similar to that found in phones and computers. "We no longer have to compromise function to achieve the optimal form for interfacing with our biology."

As a next step, scientists will use the devices to better understand neurological disease, test drugs and therapies that have clinical potential, and compare different patient-derived cell models. This understanding will then enable a better grasp of individual differences that may account for the wide variation of outcomes seen in neurological rehabilitation.

"As scientists, our goal is to make laboratory research as clinically relevant as possible," said Kristen Cotton, research assistant in Dr. Franz's lab. "This 3-D platform opens the door to new experiments, discovery and scientific advances in regenerative neurorehabilitation medicine that have never been possible."

Credit: 
Northwestern University